: Novel diagnostic and therapeutic tools that can enable earlier and more specific detection, as well as enhance efficacy are critically needed to improve patient outcomes, in particular in melanoma and malignant brain tumors studied in this Center. For example, such tools should enable the operating surgeon to directly visualize tumor margins and metastatic disease spread to lymph nodes, while identifying adjacent vital neurovascular structures. Such structures may be difficult to visualize, thus putting them at risk for injury. Unfortunately, while nanoparticles have a number of desirable features permitting the addition of new functionalities to create a more potent, tumor-directed imaging and/or therapeutic platform, such molecularly targeted, multimodality particles that can improve diagnostic accuracy and/or triage patients to appropriate treatment arms, have been slow to advance to the clinical trial stage. The vision of the MSKCC-Cornell Center for Translation of Cancer Nanomedicines (MC2TCN) is to advance, translate, and disseminate a suite of ultrasmall (<10 nm) multimodality (PET/optical) silica-organic hybrid nanoparticles with tunable size, brightness, and geometry that, as a result of their proven favorable pharmacokinetics, clearance profiles and tumor-to-background ratios in human patients, have the potential to overcome these limitations and dramatically impact the way we diagnose and treat cancer patients. This includes the development and implementation of intraoperative optical detection tools to improve cancer localization, staging, and treatment, as well as the development of optimized therapeutic platforms that enhance delivery and therapeutic index relative to existing technologies. The proposed Center is focused on initial development efforts of diagnostic particle probes, fluorescent core-shell silica nanoparticles referred to as Cornell dots or C dots, which have already received FDA investigational new drug (IND) approvals for first in-human clinical trials. This successful work, for the first time in human patients, has validated the taret or clear approach of <10 nm nanoparticles pursued in this Center, opening the door to transformative research and development of new clinically promising classes of nanoparticles and their applications in cancer diagnostics and therapeutics. Transitioning to water-based synthetic approaches proposed here will enable cost-effective creation of novel diagnostic and therapeutic particle platforms with sizes <10 nm. These ultrasmall particle platforms will exhibit high brightness for maximum detection sensitivity by altering particle core composition, lead to particle geometries (rings vs. spheres) with increased surface area for maximizing drug loading capacity, and address the effects of particle size and surface chemistry heterogeneity on PK, clearance profiles and target-to-background ratios - key issues in the use of nanomaterials in nanomedicine. Informed by the encouraging results of the first-in-human clinical trials with first generation multimodal C dots, built on many years of collaborative research between investigators of the proposed multi-institutional, multi-disciplinary team, we envision that the proposed work defined by the framework of this Center and by the use of same-sized particle platforms exhibiting improved and significantly enhanced capabilities has a realistic chance to change the paradigm of cancer care applications pursued herein.
Metastatic melanoma, one of the fastest rising cancers in the United States, and malignant brain tumors have a very poor prognosis, and offer very few treatment options. We propose a multi-institutional, multi-disciplinary Center to advance, translate, and disseminate a suite of ultrasmall (<10 nm) multimodality (PET/optical) silica- organic hybrid nanoparticles with tunable size, brightness, and geometry. Further, as a result of their proven favorable pharmacokinetics, clearance profiles, and tumor-to-background ratios in human patients, these particle probes offer a more realistic solution to overcome existing limitations, and should dramatically impact cancer care.
|Grüner, Florian; Blumendorf, Florian; Schmutzler, Oliver et al. (2018) Localising functionalised gold-nanoparticles in murine spinal cords by X-ray fluorescence imaging and background-reduction through spatial filtering for human-sized objects. Sci Rep 8:16561|
|Chen, Feng; Ma, Kai; Madajewski, Brian et al. (2018) Ultrasmall targeted nanoparticles with engineered antibody fragments for imaging detection of HER2-overexpressing breast cancer. Nat Commun 9:4141|
|Nath, Pooja; Mangal, Rahul; Kohle, Ferdinand et al. (2018) Dynamics of Nanoparticles in Entangled Polymer Solutions. Langmuir 34:241-249|
|Chen, Feng; Zhang, Xiuli; Ma, Kai et al. (2018) Melanocortin-1 Receptor-Targeting Ultrasmall Silica Nanoparticles for Dual-Modality Human Melanoma Imaging. ACS Appl Mater Interfaces 10:4379-4393|
|Ma, Kai; Gong, Yunye; Aubert, Tangi et al. (2018) Self-assembly of highly symmetrical, ultrasmall inorganic cages directed by surfactant micelles. Nature 558:577-580|
|He, Frank; Chiou, Aaron E; Loh, Hyun Chae et al. (2017) Multiscale characterization of the mineral phase at skeletal sites of breast cancer metastasis. Proc Natl Acad Sci U S A 114:10542-10547|
|Chen, Feng; Ma, Kai; Benezra, Miriam et al. (2017) Cancer-Targeting Ultrasmall Silica Nanoparticles for Clinical Translation: Physicochemical Structure and Biological Property Correlations. Chem Mater 29:8766-8779|
|Chen, Feng; Ma, Kai; Zhang, Li et al. (2017) Target-or-Clear Zirconium-89 Labeled Silica Nanoparticles for Enhanced Cancer-Directed Uptake in Melanoma: A Comparison of Radiolabeling Strategies. Chem Mater 29:8269-8281|
|Yoo, B; Ma, K; Wiesner, U et al. (2017) Expanding Analytical Tools for Characterizing Ultrasmall Silica-based Nanoparticles. RSC Adv 7:16861-16865|
|Kim, Sung Eun; Zhang, Li; Ma, Kai et al. (2016) Ultrasmall nanoparticles induce ferroptosis in nutrient-deprived cancer cells and suppress tumour growth. Nat Nanotechnol 11:977-985|
Showing the most recent 10 out of 12 publications